Gsk Plc · LSE:GSK
Gsk — Merger or Acquisition (February 2026)
10 slides from Gsk's merger presentation, Feb 25, 2026
Slide 1: Agreement to acquire 35Pharma Inc.
25 February 2026 Agreement to acquire 35Pharma Inc. Lead asset: HS235, a potential best-in-class medicine for the treatment of cardiopulmonary diseases gsk.com
Slide 2: Speakers
Speakers Nina Mojas Kaivan Khavandi President, Global Product SVP R&D Head Respiratory, Strategy Immunology & Inflammation
Slide 3: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly t
Slide 4: Agreement to acquire 35Pharma and HS235
Agreement to acquire 35Pharma and HS235 A potentially best-in-class activin signalling inhibitor Strategic rationale Financial considerations • Pulmonary Hypertension (PH) is a group of diseases with 5yr survival often ~50%1 Deal consideration • HS235 potential BIC activin-signalling inhibitor in Gr
Slide 5: Pulmonary Hypertension: high-impact, under-served, group of diseases
Pulmonary Hypertension: high-impact, under-served, group of diseases With few disease modifying treatment options available, the PH market is set for significant growth Treatment options Group 1 Group 2 PAH PH HFpEF Group 1 Group 2 PAH PH HFpEF • Endothelin Receptor • No approved treatments Total An
Slide 6: Go to market model will be highly focused around PH centers of excellence
Go to market model will be highly focused around PH centers of excellence Number of PH centers by state in the US1 • Patients with severe PH are Centers/ managed in centers of excellence State by pulmonologists & cardiologists • Highly focused specialty launch investment ~100 PH centers in the US So
Slide 7: Pulmonary Hypertension: a high-impact, under-served, and adjacent opportunity for GSK
Pulmonary Hypertension: a high-impact, under-served, and adjacent opportunity for GSK PH represents the next frontier in cardiopulmonary medicine – where GSK’s biology and delivery platforms can lead Group 1 • PH leads to progressive heart failure and premature death; Pulmonary arterial Severe burde
Slide 8: HS235 is next-gen activin/GDF inhibitor with BIC potential
HS235 is next-gen activin/GDF inhibitor with BIC potential Early clinical data show no evidence of bleeding-related AEs and lower erythropoietic signal PH is progressive and life-limiting, with A differentiated profile expected to improve tolerability high symptom burden and sub-optimal by sparing B
Slide 9: GSK to progress HS235 clinical development at pace
GSK to progress HS235 clinical development at pace A potentially best-in-class activin signalling inhibitor Clinical development RI&I portfolio impact • Completed Phase I healthy volunteer Offers new opportunities within our RI&I clinical trials demonstrating favorable portfolio to achieve broader c
Slide 10: 10
10